PT  - JOURNAL ARTICLE
AU  - Kurita, Junko
AU  - Sugawara, Tamie
AU  - Sugishita, Yoshiyuki
AU  - Ohkusa, Yasushi
TI  - No Excess Mortality of COVID-19 in Japan until April and May, 2020
AID  - 10.1101/2020.07.09.20143164
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.09.20143164
4099  - http://medrxiv.org/content/early/2020/08/07/2020.07.09.20143164.short
4100  - http://medrxiv.org/content/early/2020/08/07/2020.07.09.20143164.full
AB  - Background As of the end of June, 2020, the COVID-19 outbreak exhibited its highest peak on April 3. Nevertheless, no remarkable excess mortality attributable to COVID-19 has been observed.Object We sought to quantify excess mortality in April using the National Institute of Infectious Diseases (NIID) model.Method We applied the NIID model to deaths of all causes from 1987 up through May, 2020.Results Results show no significant excess mortality in March, April or May, 2020, when the COVID-19 outbreak affected Japan most.Discussion and Conclusion Because changes in application rule of the International Classification of Diseases in 2017 affected the number of pneumonia deaths drastically, we were unable to use pneumonia deaths to estimate excess mortality. it might be important to continue to monitor excess mortality of COVID-19 carefully after June 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMinistry of Health, Labour and Welfare. Preliminary statistics on demographics https://www.mhlw.go.jp/toukei/list/81-1a.html